Similar articles

• Reevaluating Piperacillin-Tazobactam Mortality.

  Darlow CA, Gerada A, Hope W. Darlow CA, et al. JAMA Intern Med. 2024 Oct 1;184(10):1267-1268. doi: 10.1001/jamainternmed.2024.4114. JAMA Intern Med. 2024. PMID: 39186305 No abstract available.
• Reevaluating Piperacillin-Tazobactam Mortality.

  Hsu CK, Lai CC. Hsu CK, et al. JAMA Intern Med. 2024 Oct 1;184(10):1267. doi: 10.1001/jamainternmed.2024.4111. JAMA Intern Med. 2024. PMID: 39186290 No abstract available.
• Reevaluating Piperacillin-Tazobactam Mortality.

  Chao CT. Chao CT. JAMA Intern Med. 2024 Oct 1;184(10):1268. doi: 10.1001/jamainternmed.2024.4117. JAMA Intern Med. 2024. PMID: 39186287 No abstract available.
• Piperacillin/tazobactam for surgical prophylaxis during pancreatoduodenectomy: meta-analysis.

  Kumar J, Reccia I, Carneiro A, Podda M, Virdis F, Machairas N, Nasralla D, Arasaradnam RP, Poon K, Gannon CJ, Fung JJ, Habib N, Llaguna O. Kumar J, et al. BJS Open. 2024 May 8;8(3):zrae066. doi: 10.1093/bjsopen/zrae066. BJS Open. 2024. PMID: 38869238 Free PMC article.
• Piperacillin-tazobactam vs. carbapenems for treating hospitalized patients with ESBL-producing Enterobacterales bloodstream infections: A systematic review and meta-analysis.

  Gatti M, Cojutti PG, Pea F. Gatti M, et al. J Glob Antimicrob Resist. 2024 Dec;39:27-36. doi: 10.1016/j.jgar.2024.08.002. Epub 2024 Aug 21. J Glob Antimicrob Resist. 2024. PMID: 39173739